2015

02/11/2015

Hymovis®, which was recently approved by the FDA in the U.S., is a highly viscoelastic hydrogel (HYADD®4) engineered using a proprietary process that increases lubrication and shock absorption properties

PARSIPPANY, N.J., Nov. 2, 2015 – Fidia Farmaceutici, a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products, and its wholly owned subsidiary, Fidia Pharma USA Inc., will present Hymovis® (high molecular weight viscoelastic hyaluronan) at the American…
09/09/2015

Fidia Farmaceutici’s Italian excellence grows in the US market with its latest generation hyaluronic acid

The FDA’s Center for Devices and Radiological Health (CDRH) has approved the PMA (Pre Market Approval) application for Hymovis from Fidia Farmaceutici, indicated for the intra-articular therapy of osteoarthritis based on hyaluronic acid, designed to remain longer in the joint. This information comes…

Health
Products
Website

Find out more about Fidia’s product portfolio:

Go to the website

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint healthcare
- ophthalmology
- wound care
- dermatology
- neurology
- dermo-aesthetics